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INTRODUCTION
Pheochromocytoma is rare but a critical tumor of chromaf-
fin cells, which is frequently considered in the evaluation of
hypertension, arrhythmia, or panic disorder and in the follow-
up of patients with particular genetic diseases (1, 2). Pheochro-
mocytoma is a one of the potentially fatal causes of childhood
hypertension and accounts for about 1% of pediatric hyper-
tensive patients (3, 4). 
Because pheochromocytoma is more common in adults than
in children, most of the data available on its behavior and
management have been based on adults, and thus the etiopa-
thogenesis and management of pediatric pheochromocytoma
remains obscure (1). However, differences in the behavior of
this tumor in children require special considerations to ensure
optimal management of such pediatric population. 
This study aims to review one of the big pediatric series
ever studied at a single medical center, and to make a brief
review on the literature concerning advances in the genetics,
biochemical diagnosis, localization, and management of phe-
ochromocytoma. 
MATERIALS AND METHODS
Between 1984 and 2002 we treated 15 patients with phe-
ochromocytoma: 11 males and 4 females with an average age
at surgery of 11.7 yr ranging from 6 yr 9 months to 15 yr 7
months.
We retrospectively evaluated the information available on
each patient, including age, sex, clinical characteristics, diag-
nostic methods, treatment, pathologic finding, and outcome.
Tumors were localized by ultrasonography, computed tomog-
raphy (CT), magnetic resonance imaging (MRI), and by
MIBG scintigraphy. For some patients, intravenous pyelog-
raphy (IVP) was conducted. Localized disease was defined as
the case without a pathologic finding of surrounding tissue
invasion, regional disease as disease with a pathologic finding
of surrounding tissue invasion. Metastatic disease was defined
as disease with distant metastases. The findings that are dis-
closed by pathologic examination are as follows: surrounding
tissue invasion, capsular invasion, vascular invasion, necrosis,
pleomorphism, atypical mitosis, cyst formation, and lymphoid
reaction.
In this study, the mean follow-up after resection was 95
months (5-223 months). Statistical evaluations were performed
using the SPSS package (chi-squre test and Fisher’s exact test). 
RESULTS
One patient (6.6%) only was associated with von Hippel
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Experience with Surgical Excision in Childhood Pheochromocytoma
Pheochromocytoma is one of the potentially fatal causes of childhood hypertension.
The study aims to analyze the results of our experiences in pheochromocytomas
and the long-term results of its surgical treatment in children. The records of 15 chil-
dren (11 boys, 4 girls) treated for pheochromocytoma in our unit during the period
of 1984 and 2002 were reviewed retrospectively. The average age at surgery was
11.7 yr (range 6 yr 9 months-15 yr 7 months). Localized disease is defined as the
cases without the invasion of surrounding tissue, regional disease as the invasion of
surrounding tissue and metastatic disease as distant metastases. The mean follow-up
after pheochromocytoma excision was 95 months (range 5 to 221 months). Tumors
were located in the adrenal gland in 11 (bilaterally in 4) and extra-adrenally in 4. Local-
ized disease occurred in 14 patients and regional disease in one. Only one patient
was associated with von Hippel Lindau syndrome. Adrenalectomy or total excision
of extra adrenal tumor was performed. Four patients (26.7%) recurred after the first
operation (at 2 yr 9 months to 14 yr) and regional disease recurred in one patient
three times. Early diagnosis, surgical excision, and long-term follow up are most impor-
tant for the appropriate treatment of childhood pheochromocytoma.
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Lindau disease. This patient had a father with a history of
pheochromocytoma, which was treated by surgical resection
when he was 45 yr old. 
Symptoms at presentation are listed in Table 1. The out-
standing and common symptoms were sweating and hyper-
tension. Hypertension was noted in all patients but one. Their
overall mean arterial blood pressures (ABPs) were 160 mmHg
ranging from 140 to 190 mmHg and 100 mmHg ranging
from 70 to 120 mmHg for systolic and diastolic pressure
respectively. Mean time between symptom onset and diagno-
sis was 11.9 months ranging from 1 month to 48 months.
Abnormal electrocardiography (left ventricular hypertrophy;
n=7, tachycardia; n=2, prolonged QT interval; n=4), hyper-
tensive retinopathy (n=5), cardiomegaly at chest radiography
(n=6), and hypertensive encephalopathy (n=2) were also found.
The average 24-hr daily urinary vanillylmendelic acid
(VMA) levels were 28.8 mg/24 hr (range 0.6-52.8 mg/24 hr):
all patients had a value higher than the upper limit of normal
range (normal value 0.7-6.9 mg/24 hr). Elevated levels of
serum epinephrine were found in one of the 15 patients only,
and elevated levels of norepinephrine in three. A CT scan was
performed on all patients. 
123I-metaiodobenzylguanidine
(MIBG) scintigraphy was performed in ten patients and intra-
venous pyelography in four. The other diagnostic methods used
were abdomen ultrasonography, and renal scanning. Bone scans
were performed in six patients to detect bone metastasis, and
brain MRI and EEG done in two patients who appeared symp-
toms of hypertensive encephalopathy.
Preoperative treatment with the phenoxybenzamine, non-
selective  -adrenergic antagonist, was performed in all patients
for a median of 14 days (range 7-21 days). The mean dose
administered was 1.4 mg/kg/day (range 0.2-2.44 mg/kg/
day). Prazocine, hydralazine, nifedipine, digoxine, lasix, or
propranolol was also used intermittently. Preoperative hydra-
tion was performed in 11 patients. The ABPs of all patients
were controlled and no intraoperative ABP fluctuation was
observed.
Table 2 shows the clinical characteristics and outcomes of
surgical resection. The transperitoneal approach was adopted
in all patients, as we preferred a subcostal incision. Fourteen
patients had localized disease and one patient regional disease.
None had metastatic disease. The tumors were in the right
side adrenal gland in 3 patients, in the left side gland in 4,
bilaterally in 4, and extra-adrenally in 4. Three of the four
extra-adrenal pheochromocytomas were located in the organ
of Zuckerkandle and one was at the left renal hilum. Seven
patients with ipsilateral adrenal pheochromocytoma under-
went ipsilateral adrenalectomy, including cortex sparing ad-
renalectomy (n=2), and contralateral adrenal gland biopsy
Symptom No. of patients %






Weight loss 7 46.6
Visual disturbance 6 40




Easy fatigability 2 13.3
Chest pain 1 6.6
Loss of consciousness 1 6.6




Table 1. Symptoms presented by pheochromocytoma patients
Case Age at operation Localization Operation Pathology Outcome Sex
1 10 yr 1 mon F Right adrenal Rt. adrenalectomy Localized Recovery
2 10 yr 1 mon M Bilateral Bilat. adrenalectomy Localized Recovery
3 13 yr 6 mon M Extra adrenal Mass excision Localized Recurrence
4 6 yr 9 mon M Extra adrenal Mass excision Regional Recurrence
5 15 yr 7 mon M Left adrenal Lt. adrenalectomy
� Localized Recovery
6 12 yr 4 mon M Bilateral Bilat. adrenalectomy Localized Recurrence
7 14 yr F Extra adrenal Mass excision Localized Recovery
8 8 yr 5 mon M Left adrenal Lt. adrenalectomy Localized Recovery
9 12 yr 7 mon F Bilateral Bilat. adrenalectomy Localized Recurrence
10 13 yr 1 mon M Left adrenal Lt. adrenalectomy
�+ rt. biopsy Localized Recovery
11 10 yr 6 mon M Extra adrenal Mass excision Localized Recovery
12 12 yr 11 mon M Right adrenal  Rt. adrenalectomy Localized Recovery
13 14 yr 3 mon M Right adrenal Rt. adrenalectomy Localized Recovery
14 11 yr 2 mon F Left adrenal Lt. adrenalectomy Localized Recovery
15* 10 yr 3 mon M Bilateral Bilat. adrenalectomy
� Localized Recovery
Table 2. Clinical characteristics and outcome
*: Family history of pheochromocytoma (his father), 
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(n=1). Four patients with bilateral pheochromocytoma under-
went bilateral adrenalectomy, including cortex-sparing ad-
renalectomy (n=1). Four patients with an extra-adrenal phe-
ochromocytoma received total excision, which included ipsi-
lateral nephrectomy in one case with regional disease. The
mean size of the removed masses was 4 cm ranging from 1.2
to 6 cm.
After surgery, thirteen of the 15 patients became normoten-
sive state without hypertension medication. However, two
patients required medical therapy for satisfactory control of
blood pressure. There were several complications including
operation site bleeding, ureter injury, lugol induced hypothy-
roidism and hypocortisonism. All complications were resolved
without sequelae (Table 3). No operative mortality occurred
in our series.
There was no difference of these pathologic results between
recurred and non-recurred cases or between regional disease
and localized disease (Table 4).
The mean follow up period to date is 95 months (5-223
months). 
After tumor removal, four patients recurred with the dura-
tion range of 2 yr 9 months to 14 yr; three patients with local-
ized disease and one patient with regional disease (Table 5).
The recurrent sites include lung parenchyme, pancreas, ad-
renalectomy site, and the organ of Zukerkandle. One patient
with recurrence in lung received wedge resection and have no
recurrence. One patient with pancreatic recurrence was given
MIBG therapy and was lost to follow up later. One patient
with bilateral adrenalectomy site recurrence also received
MIBG therapy and subsequently mass excision for hyperten-
sion control but expired due to hypertensive encephalopathy.
Thus, MIBG therapy was administered to two recurred pa-
tients but its effect was meager. Of the four recurrent cases,
one patient with regional disease had three separate recurrences.
The first and second recurrent masses were surgically excised
but the third recurrent mass has been kept under observation
with anti-hypertensive medication, without surgical excision.
DISCUSSION
Rare as it is, pheochromocytoma is a chromaffin cell tumor
that must be considered in patients with hypertension, auto-
nomic disturbances, panic attacks, adrenal incidentalomas,
or familial disease featuring a predisposition to develop pheo-
chromocytoma (1, 2). About 5-20% of these extremely rare
tumor are found in the pediatric population, and with an inci-
dence of two per million, pheochromocytoma accounts for
secondary hypertension in 0.5% of children, and is more com-
mon in preadolescent boys and teenage girls (3-6).
There are some differences in behavior of pheochromocytoma
between the pediatric and adult populations. Most studies
have confirmed male preponderance and greater tendency for
familial occurrence and multi-focality (43% in children vs.
30% in adults), an increased incidence of extra-adrenal tumors
(30-40% in children vs. 10% in adults), and similar/lower
risks of a malignant pheochromocytoma (3.5%) (7, 8). Our
experience revealed a male predominance (73%), a preadoles-
cent tendency (mean age: 11.7 yr), an extra-adrenal location
Complication No. of patients (%) Treatment
Bleeding 1 (6.6) Operation
Ureter injury 1 (6.6) Primary repair
Lugol induced hypothyroidism 1 (6.6) Oral medication
Hypocortisonism 1 (6.6) Oral medication
Table 3. Postoperative complication
Pathologic factor No. of patients p-value
Surrounding tissue invasion (+) 2 0.164
(-)1 7
Capsular invasion (+) 7 0.297
(-) 12
Vascular invasion (+) 0 NA
(-) 19
Necrosis (+) 2 0.322
(-)1 7
Pleomorphism Mild 10 0.255
Moderate 9
Atypical mitosis (+) 0 NA
(-)1 9
Cyst formation (+) 2 0.322
(-)1 7
Lymphoid reaction (+) 2 0.678
(-)1 7
Table 4. Analysis of pathologic factors influencing recurrence
Case Localization Recurrence
Interval
Recurrence site Treatment Outcome F/U (After 
recurrence)
1st operation
3 Extraadrenal Mass excision 14 yr Chest LLL, RLL Excision (VATS) 4 yr 7 mon Recovery
4 Extraadrenal Mass excision 1. 8 yr 3 mon 1. Extraadarenal 1. Excision Extradarenal mass
2. 10 yr 3 mon 2. Extraadarenal 2. Excision Medication
3. 13 yr 3. Extraadarenal 3. Observation 1 yr 1 mon (antihypertensive)
6 Bilateral Bilat. Adrenalectomy 6 yr 3 mon Pancreas head and tail MIBG therapy F/U loss F/U loss
9 Bilateral Bilat. Adrenalectomy 2 yr 9 mon Bilat. adrenal gland site MIBG therapy 8 yr 6 mon Expired
+ Mass excision
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tendency (26.6%), and lower malignant development (0%),
but the incidence of multifocal locations (26.6%).And a famil-
ial tendency (6.6%) was lower than that found in the litera-
tures (7, 8). 
The presentation of pheochromocytoma is variable, and
patients may often be asymptomatic (9). Children most com-
monly present with signs and symptoms related to hyperten-
sion including headache. Some symptoms of pheochromocy-
toma include sweating, visual complaints, nausea, vomiting,
weight loss, polydipsia and polyuria and these are more com-
mon in children than in adults (7, 10). In our series, symp-
toms such as hypertension, sweating, headache, palpitations
and vomiting tended to agree with findings commonly pre-
sented in the literature. Although children with pheochromo-
cytoma usually present with sustained hypertension, 80% of
our patients presented with paroxysmal hypertension.
The most important consideration when choosing an initial
biochemical test is the reliability of the test in terms of exclud-
ing pheochromocytoma. The diagnosis of pheochromocytoma
usually requires biochemical data indicating excessive cate-
cholamine production by the tumor, which is performed by
measuring vanillylmendelic acid (VMA) and metanephrine
24-hr urinary excretion, giving a sensitivity and specificity
of 80-100% (10-13). A positive correlation between the size
of a tumor and the urinary VMA level has been reported (10).
In our series, all patients had an elevated level of urine VMA,
but we cannot confirm a positive correlation between tumor
size and the urinary VMA level (p>0.05). Further advances,
measurements of plasma free metanephrines, normetanephrine,
metanephrine, and the respective o-methylated metabolites
of NE or epinephrine represent recently developed. This devel-
opment is helpful for the diagnosis of pheochromocytoma (11,
12).
Preoperative imaging procedures are essential to the accu-
rate and noninvasive localization of the number, site, size, and
extension of these lesions for successful surgical management.
In a recent study of 282 patients in which MR imaging, CT,
and MIBG were compared, MR imaging was found to be the
most sensitive technique for localization of adrenal and extra-
adrenal pheochromocytomas. Computed tomography and
magnetic resonance imaging have less than ideal sensitivities.
131I-metaiodobenzylguanidine (MIBG) scanning and positron
emission tomography have been used in identifying primary,
recurrent and metastatic tumors (2, 7). CT and/or ultrasonog-
raphy were used in all patients and allowed the visualization
of the tumor site, the tumor size and of tumor extension. MI-
BG scanning was also used to detect recurrent and metastatic
tumors in 10 patients and recurrent tumor were detected in
four patients. 
The most important aspect of preoperative preparation is
the identification and treatment of hypertension and of other
sequelae of catecholamine-induced vasoconstriction. Most
centers support to place patients on adrenergic blockades such
as phenoxybenzamine and upon a positive fluid balance pre-
operatively (2, 7, 13-16). Current guidelines recommend phe-
noxybenzamine dosages of 160 mg at the maximum per day,
divided into four equal doses every 6 hr, which should be grad-
ually tapered over a 10- to 14-day period (13). 
Surgical excision of pheochromocytoma has been performed
using a transabdominal approach, with palpation of the contra-
lateral adrenal gland and sympathetic chain to detect additional
tumors (2). Compared to open operations, laparoscopic surgery
has the advantages of less postoperative pain, reduced postop-
erative stay, and a reduced need for analgesics and of improved
functional and cosmetic results. Therefore, laparoscopic surgery
is associated with reduced morbidity versus open surgery in
experienced hands (2, 6, 7, 14, 17-21). Despite many adult
studies, few reports have described the results of this laparo-
scopic technique in pediatric patients, and more data is needed
to confirm benefits of the laparoscopic approach in pediatric
patients.
Because recurrent pheochromocytomas may develop by 20%
to 33% of patients with familial syndrome undergoing par-
tial adrenalectomy, bilateral adrenalectomy is recommended
in bilateral pheochromocytoma, especially associated with
hereditary syndromes. However, the range of 25% and 33%
of patients undergoing bilateral adrenalectomy develop adis-
onism crisis at certain point of time, and the attendant mor-
tality rates are high. Moreover, 30% of patients develop clini-
cally significant fatigue, and 48% consider themselves hand-
icapped (22, 23). Therefore, a minimally invasive approach,
such as bilateral adrenal cortex-sparing tumor enucleation,
certainly presents as an intriguing alternative to bilateral ad-
renalectomy, especially in those associated with hereditary
syndromes. Given the greater likelihood of a metachronous
recurrence in children, consideration should be given adrenal-
sparing surgery in selected patients (2, 7, 13). We performed
cortex-sparing adrenalectomy in two ipsilateral adrenal pheo-
chromocytomas and in one bilateral adrenal pheochromocy-
toma. The three patients that underwent cortex-sparing ad-
renalectomy survived without recurrence or hypocortisonism
(follow-up periods: 13 yr 5 months, 11 yr 5 months, and 5
months), but we were not able to confirm a significant differ-
ence between the cortex spared adrenalectomy group and the
cortex no-spared adrenalectomy group in terms of the post-
operative cortisol level. 
Malignant pheochromocytoma is rare in childhood and the
prognosis of this tumor in children is not well known. Present-
ing signs, the localizations of the primary tumor or of meta-
stases, and the course of malignant pheochromocytoma in chil-
dren do not seem to be significantly different from those in
adults (24). In cases of malignant pheochromocytoma, multi-
modality treatments can be used. However, the benefits of
chemotherapy,  131I-MIBG therapy, external radiation and
octreotide remained undetermined. The mean 5-yr survival
rate for malignant pheochromocytomas is about 40% (13, 24).
Ten percent of pheochromocytoma are associated with fa-
milial cancer syndromes, such as multiple endocrine neoplasmTreatment of Childhood Pheochromocytoma 405
type 2, von Hippel-Lindau, neurofibromatosis type 1, and
familial carotid body tumors in which germ-line mutation
of the RET, VHL, or NF1 genes have been found (2, 6, 7).
Patients with a positive family history, bilateral adrenal pheo-
chromocytoma, recurrent or multiple pheochromocytoma,
and symptoms at a younger age should undergo clinical or
genetic testing mutations of the von Hippel-Lindau or RET
genes. Succinate dehydrogenase mutation has been described
previously in five families with familial paraganglioma syn-
drome (25-27). In both the sporadic and familial forms of
pheochromocytoma, allelic losses at 1p, 3p, 17p, and 22q have
been reported, yet the molecular pathogenesis of these tumors
is largely unknown (28). In one patient with familial pheochro-
mocytoma, the VHL genes were positive.
Recurrence in pheochromocytoma has been reported to
range from 10% to 40% (10, 29-31), which concurs with
our recurrence rate (26.6%). In the current study, recurrence
occurred in three patients with localized tumors and in one
with regional tumors. However no significant difference was
observed between localized and regional tumors in this regard.
In three of four patients with recurrence, surgical resection has
produced good results in terms of the relief of hypertension,
but MIBG therapy, which was performed for 2 patients, has
produced no symptom relief. 
Our conclusion is that early diagnosis and total excision
constitute proper management in pheochromocytoma, and
that the treatment of choice in recurred pheochromocytoma
is surgical excision, if possible. Furthermore, since the interval
between resection and recurrence varies, long-term follow-up
should be performed in pediatric pheochromocytoma. 
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